These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 37985504)
1. Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative. Kanagalingam T; Khan T; Sultan N; Cowan A; Thain J; Hoy C; Ledger S; Clemens KK Arch Osteoporos; 2023 Nov; 18(1):138. PubMed ID: 37985504 [TBL] [Abstract][Full Text] [Related]
2. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5. Dave V; Chiang CY; Booth J; Mount PF Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847 [TBL] [Abstract][Full Text] [Related]
3. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112 [TBL] [Abstract][Full Text] [Related]
4. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting. Huynh AL; Baker ST; Stewardson AJ; Johnson DF Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807 [TBL] [Abstract][Full Text] [Related]
5. Integrated Osteoporosis Care to Reduce Denosumab-Associated Hypocalcemia for Patients with Advanced Chronic Kidney Disease and End-Stage Renal Disease. Hsu CT; Deng YL; Chung MC; Tsai SF; Lin SY; Chen CH Healthcare (Basel); 2023 Jan; 11(3):. PubMed ID: 36766888 [TBL] [Abstract][Full Text] [Related]
6. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. Gopaul A; Kanagalingam T; Thain J; Khan T; Cowan A; Sultan N; Clemens KK Arch Osteoporos; 2021 Jul; 16(1):116. PubMed ID: 34319515 [TBL] [Abstract][Full Text] [Related]
7. Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population-Based Cohort Study. Cowan A; Jeyakumar N; McArthur E; Fleet JL; Kanagalingam T; Karp I; Khan T; Muanda FT; Nash DM; Silver SA; Thain J; Weir MA; Garg AX; Clemens KK J Bone Miner Res; 2023 May; 38(5):650-658. PubMed ID: 36970786 [TBL] [Abstract][Full Text] [Related]
8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V; Torregrosa V Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742 [TBL] [Abstract][Full Text] [Related]
9. Management of Osteoporosis in Chronic Kidney Disease. Nitta K; Yajima A; Tsuchiya K Intern Med; 2017 Dec; 56(24):3271-3276. PubMed ID: 29021477 [TBL] [Abstract][Full Text] [Related]
10. Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D Ikegami K; Hashiguchi M; Kizaki H; Yasumuro O; Funakoshi R; Hori S J Clin Pharmacol; 2022 Sep; 62(9):1151-1159. PubMed ID: 35383950 [TBL] [Abstract][Full Text] [Related]
11. The relationship between chronic kidney disease and denosumab-induced hypocalcemia in high-age osteoporotic patients. Horikawa A; Hongo M; Kasukawa Y; Shimada Y; Kodama H; Sano A; Miyakoshi N J Bone Miner Metab; 2022 Jul; 40(4):670-676. PubMed ID: 35641798 [TBL] [Abstract][Full Text] [Related]
12. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)]. Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221 [TBL] [Abstract][Full Text] [Related]
13. Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting. Simonini M; Bologna A; Vezzoli G Int Urol Nephrol; 2024 Oct; 56(10):3285-3293. PubMed ID: 38856936 [TBL] [Abstract][Full Text] [Related]
14. [Is denosmab really effective and safe in the care of CKD-MBD?]. Hamano T; Nakano C Clin Calcium; 2016 Sep; 26(9):1309-17. PubMed ID: 27561346 [TBL] [Abstract][Full Text] [Related]
15. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease. Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381 [TBL] [Abstract][Full Text] [Related]
16. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease. Broadwell A; Chines A; Ebeling PR; Franek E; Huang S; Smith S; Kendler D; Messina O; Miller PD J Clin Endocrinol Metab; 2021 Jan; 106(2):397-409. PubMed ID: 33211870 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of denosumab in osteoporotic hemodialysed patients. Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428 [TBL] [Abstract][Full Text] [Related]
18. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis. Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176 [TBL] [Abstract][Full Text] [Related]
19. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Souqiyyeh MZ; Shaheen FA Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700 [TBL] [Abstract][Full Text] [Related]
20. Post-craniopharyngioma surgery hypocalcemia due to denosumab use for osteoporosis: A case report. Jia L; Hu Y; Jin G Medicine (Baltimore); 2024 Sep; 103(37):e39649. PubMed ID: 39287282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]